Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro

Anaesthesia

Volumn 60, Issue 8, 2005, Pages 747-753

  Mc Donnell, Conor G ^a   Shorten, G ^a   Van Pelt, F N A M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIDAZOLAM;

ARTICLE; DRUG ANTAGONISM; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; IN VITRO STUDY; LIVER MICROSOME; MICHAELIS CONSTANT;

CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; FATTY ACIDS, MONOUNSATURATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPNOTICS AND SEDATIVES; INDOLES; MICROSOMES, LIVER; MIDAZOLAM; PYRROLES;

EID: 22944447726     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2005.04110.x     Document Type: Article

References (27)

1. Wang R, Newton DJ, Liu N, Atkins WM, Lu AYH. Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate dependent. Drug Metabolism and Disposition 2000; 28: 360-6.
2. Wilkinson GR. Cytochrome P450 3A metabolism-prediction of in vivo activity in humans. Journal of Pharmacokinetics & Biopharmacy 1996; 24: 475-90.
3. Wang TJ, Stafford RS, Ausiello JC, Chaisson CE. Randormized clinical trials and recent patterns in the use of statins. American Heart Journal 2001; 141: 957-63.
4. Feely J, McGettigan P, Kelly A. Growth in use of statins after trials is not targeted to most appropriate patients. Clinical Pharmacology and Therapeutics 2000; 67: 438-41.
5. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clinical Pharmacokinetics 1997; 32: 403-25.
6. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clinical Pharmacology and Therapeutics 1999; 66: 118-27.
7. Mazzu AL, Lasseter KC, Shamblen EC, et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clinical Pharmacology and Therapeutics 2000; 68: 391-400.
8. Ishigami M, Honda T, Takasaki W, et al. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metabolism and Disposition 2001; 29: 282-8.
9. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. British Journal of Clinical Pharmacology 1999; 48: 716-27.
10. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clinical Pharmacology and Therapeutics 1999; 66: 461-71.
11. McDonnell C, Harre S, O'Driscoll J, et al. The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. Anaesthesia 2003; 58: 899-904.
12. Bailey BL, Pace NL, Ashburn MA, et al. Frequent hypoxemia and apnea after sedation with midazolam and fentanyl. Anesthesiology 1990; 73: 826-30.
13. Fabre G, Rahmani R, Placidi M, et al. Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochemical Pharmacology 1988; 37: 4389-97.
14. Gorski JC, Hall SD, Jones DR, Vandenbranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 CYP3A (CYP 3A) subfamily. Biochemical Pharmacology 1994; 47: 1643-53.
15. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology 1989; 36: 89-96.
16. Wandel C, Bocker R, Bohrer H, et al. Midazolam is metabolized by at least three different cyrochrome P450 enzymes. British Journal of Anaesthesia 1994; 73: 658-61.
17. Park GR, Manara AR, Dawling S. Extra-hepatic metabolism of midazolam. British Journal of Clinical Pharmacology 1989; 27: 634-7.
18. Watkins PB. Noninvasive test of CYP 3A enzymes. Pharmacogenetics 1994; 4: 171-84.
19. Martinez C, Gervasini G, Agundez JAG, et al. Modulation of midazolam 1-hydroxylation activity in vitro by neurotransmitters and precursors. European Journal of Clinical Pharmacology 2000; 56: 145-51.
20. Oda Y, Mizurani K, Hase I, et al. Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP 3A4 in vitro. British Journal of Anaesthesia 1999; 82: 900-3.
21. Yeo KR, Yeo KW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. British Journal of Clinical Pharmacology 2001; 51: 461-70.
22. Renton KW. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochemical Pharmacology 1985; 34: 2549-53.
23. i values and impact of CYP 3A5 expression. Drug Metabolism and Disposition 1999; 27: 180-7.
24. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. British Journal of Clinical Pharmacology 1994; 37: 221-5.
25. Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Multiple-dose pharmacokinetics, pharmacodynamics and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Pharmacology and Therapeutics 1996; 60: 687-95.
26. Chaturvech AK, Rao NGS. A death due to self-administered fentanyl. Journal of Analytical Toxicology 1990; 14: 385-7.
27. Björkman S, Stanski DR, Verrota D, Harashima H. Comparative tissue concentration profiles of fentanyl and alfentanil in humans predicted from tissue/blood partition data obtained in rats. Anesthesiology 1990; 72: 865-73.